Teva Pharmaceutical Industries Limited Release: New Data Confirmed Antibodies To COPAXONE(R) Do Not Impact Its Established And Sustained Long-Term Efficacy In Multiple Sclerosis

JERUSALEM--(BUSINESS WIRE)--New data presented today at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, showed that antibodies to COPAXONE® (glatiramer acetate injection) developed in all patients with multiple sclerosis (MS) treated with COPAXONE®, but did not interfere with the efficacy of the drug. Over a mean treatment period of more than six years, patients in this cross-sectional study who were continuously treated with COPAXONE® experienced only a minimal increase in their EDSS score, indicating that the long-term efficacy of the drug was not compromised by treatment-related antibodies.

Back to news